BrUOG 326: A Phase I Dose-Escalation Study of Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With Bendamustine and Rituximab (BRiM) in Indolent Non-Hodgkin Lymphoma
Phase of Trial: Phase I
Latest Information Update: 17 May 2017
At a glance
- Drugs Vincristine (Primary) ; Bendamustine; Rituximab
- Indications Lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions
- 10 May 2017 Status changed from not yet recruiting to recruiting.
- 14 Dec 2016 Planned initiation date changed from 1 Sep 2016 to 1 Dec 2016.
- 10 Jun 2016 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019.